Clinical Trial Update: Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies [Phase 1]

View source ↗

Summary

This Phase 1 trial from Epigenetix, Inc. is evaluating a dual BET and CBP/p300 inhibitor across targeted advanced solid tumors and hematologic malignancies and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Myelofibrosis
• Myelomonocytic Leukemia
• Nut Carcinoma

Drugs mentioned

• Dual BET and CBP/p300 inhibitor

Snippet

Sponsor: Epigenetix, Inc. | Conditions: Castrate Resistant Prostate Cancer, NUT Carcinoma | Phase 1 | Status: RECRUITING